<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7291595\results\search\disease\results.xml">
  <result pre="Creative Commons Attribution 4.0 Licensefmb-2020-0063.pdf Abstract A new coronavirus, severe" exact="acute" post="respiratory syndrome coronavirus 2, was first discovered in Wuhan,"/>
  <result pre="Commons Attribution 4.0 Licensefmb-2020-0063.pdf Abstract A new coronavirus, severe acute" exact="respiratory" post="syndrome coronavirus 2, was first discovered in Wuhan, China,"/>
  <result pre="Attribution 4.0 Licensefmb-2020-0063.pdf Abstract A new coronavirus, severe acute respiratory" exact="syndrome" post="coronavirus 2, was first discovered in Wuhan, China, in"/>
  <result pre="virus. We hope this review will be helpful to prevent" exact="viral" post="infections in outbreak countries and regions. Keywords:â€‚ clinical characteristics"/>
  <result pre="We hope this review will be helpful to prevent viral" exact="infections" post="in outbreak countries and regions. Keywords:â€‚ clinical characteristics epidemiology"/>
  <result pre="reported in Wuhan, Hubei Province, China, was classified as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee"/>
  <result pre="in Wuhan, Hubei Province, China, was classified as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on"/>
  <result pre="Wuhan, Hubei Province, China, was classified as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy"/>
  <result pre="(SARS-CoV-2) by the International Committee on Taxonomy of VirusesÂ [1]." exact="Infection" post="has spread to approximately 184 regions and countries including"/>
  <result pre="Africa, Europe and Australia [2]. As of April 7, the" exact="total" post="number of infections on the Chinese mainland was 83,071"/>
  <result pre="Australia [2]. As of April 7, the total number of" exact="infections" post="on the Chinese mainland was 83,071 (FigureÂ 3A), the"/>
  <result pre="infections on the Chinese mainland was 83,071 (FigureÂ 3A), the" exact="total" post="number of recovered patients was 77,468 (FigureÂ 3B) and"/>
  <result pre="Symptoms of this virus include fever, cough, shortness of breath," exact="leukopenia" post="and pneumonia in both lungs [5]. Patients of advanced"/>
  <result pre="this virus include fever, cough, shortness of breath, leukopenia and" exact="pneumonia" post="in both lungs [5]. Patients of advanced age (&amp;gt;50Â"/>
  <result pre="is affecting younger people: even children [7]. Patients with severe" exact="viral" post="infections need intensive care and are at high risk"/>
  <result pre="affecting younger people: even children [7]. Patients with severe viral" exact="infections" post="need intensive care and are at high risk of"/>
  <result pre="death [5]. However, except among elderly cases and those with" exact="chronic" post="disease, the mortality rate of COVID-19 appears to be"/>
  <result pre="[9]. The other coronaviruses are 229E, HKU1, OC43, NL63, severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)-CoV"/>
  <result pre="The other coronaviruses are 229E, HKU1, OC43, NL63, severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS)-CoV [9â€&quot;12]."/>
  <result pre="other coronaviruses are 229E, HKU1, OC43, NL63, severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS)-CoV [9â€&quot;12]. Of"/>
  <result pre="OC43, NL63, severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS)-CoV [9â€&quot;12]. Of these, 229E, HKU1, OC43 and"/>
  <result pre="NL63, severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS)-CoV [9â€&quot;12]. Of these, 229E, HKU1, OC43 and NL63"/>
  <result pre="relatively low pathogenicity [10,13,14]. SARS-CoV and MERS-CoV can cause fatal" exact="pneumonia" post="with death rates of 10 and 37%, respectively [11,15]."/>
  <result pre="Hopkins resource center). Currently, specific vaccines and medicine for SARS-CoV-2" exact="infection" post="are being developed [16]. This paper summarizes the epidemiological,"/>
  <result pre="Influenza Data by Chinese health authorities and the Centers for" exact="Disease" post="Control and Prevention (CDC) of America [8]. It was"/>
  <result pre="and Prevention (CDC) of America [8]. It was named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) by theÂ International Committee"/>
  <result pre="Prevention (CDC) of America [8]. It was named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) by theÂ International Committee on"/>
  <result pre="(CDC) of America [8]. It was named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) by theÂ International Committee on Taxonomy"/>
  <result pre="on Taxonomy of Viruses on 11 February 2020 [1]. The" exact="disease" post="caused by SARS-CoV-2 was named COVID-19 by the World"/>
  <result pre="dromedary camels [19] (TableÂ 1). Bats and minks may be" exact="intermediate" post="hosts of SARS-CoV-2 because SARS-CoV-2 shares 96.2% homology with"/>
  <result pre="the snake and bamboo rat have also been considered as" exact="intermediate" post="hosts of SARS-CoV-2. Snakes are reportedly the most likely"/>
  <result pre="host. The bamboo rat was also predicted to be an" exact="intermediate" post="host of SARS-CoV-2 [22]. Scientists are currently working to"/>
  <result pre="currently working to identify the source of SARS-CoV-2, including possible" exact="intermediate" post="animal vectors. Table 1. Comparison between severe acute respiratory"/>
  <result pre="including possible intermediate animal vectors. Table 1. Comparison between severe" exact="acute" post="respiratory syndrome coronavirus 2, severe acute respiratory syndrome coronavirus"/>
  <result pre="possible intermediate animal vectors. Table 1. Comparison between severe acute" exact="respiratory" post="syndrome coronavirus 2, severe acute respiratory syndrome coronavirus and"/>
  <result pre="intermediate animal vectors. Table 1. Comparison between severe acute respiratory" exact="syndrome" post="coronavirus 2, severe acute respiratory syndrome coronavirus and Middle"/>
  <result pre="1. Comparison between severe acute respiratory syndrome coronavirus 2, severe" exact="acute" post="respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus."/>
  <result pre="Comparison between severe acute respiratory syndrome coronavirus 2, severe acute" exact="respiratory" post="syndrome coronavirus and Middle East respiratory syndrome coronavirus. Virus"/>
  <result pre="between severe acute respiratory syndrome coronavirus 2, severe acute respiratory" exact="syndrome" post="coronavirus and Middle East respiratory syndrome coronavirus. Virus SARS-CoV-2"/>
  <result pre="coronavirus 2, severe acute respiratory syndrome coronavirus and Middle East" exact="respiratory" post="syndrome coronavirus. Virus SARS-CoV-2 SARS-CoV MERS-CoV Ref. Outbreak year"/>
  <result pre="2, severe acute respiratory syndrome coronavirus and Middle East respiratory" exact="syndrome" post="coronavirus. Virus SARS-CoV-2 SARS-CoV MERS-CoV Ref. Outbreak year 2019"/>
  <result pre="time 5.2Â days 5Â days 5Â days [50] Clinical symptoms" exact="Fever" post="(98%), sough (77%), dyspnea (63.5%), myalgia (11.5%), malaise (35%)"/>
  <result pre="(77%), dyspnea (63.5%), myalgia (11.5%), malaise (35%) and so on" exact="Fever" post="(&amp;gt;99%), cough (62%â€&quot;100%),chills or rigor (15%â€&quot;73%), diarrhea 20%, dyspnea"/>
  <result pre="and so on Fever (&amp;gt;99%), cough (62%â€&quot;100%),chills or rigor (15%â€&quot;73%)," exact="diarrhea" post="20%, dyspnea (40%) Fever (77%), cough (90%), dyspnea (68%),"/>
  <result pre="(&amp;gt;99%), cough (62%â€&quot;100%),chills or rigor (15%â€&quot;73%), diarrhea 20%, dyspnea (40%)" exact="Fever" post="(77%), cough (90%), dyspnea (68%), sputum production (40%), odynophagia"/>
  <result pre="(43%) and headache (20%) [53,69,85] Radiology Critically ill patients with" exact="bilateral" post="multiple lobular and subsegmental areas of consolidation;mild patients with"/>
  <result pre="headache (20%) [53,69,85] Radiology Critically ill patients with bilateral multiple" exact="lobular" post="and subsegmental areas of consolidation;mild patients with bilateral ground-glass"/>
  <result pre="bilateral multiple lobular and subsegmental areas of consolidation;mild patients with" exact="bilateral" post="ground-glass opacity and subsegmental areas of consolidationalmost 100% patients"/>
  <result pre="consolidationalmost 100% patients with abnormal CT Unilateral/bilateral ground-glass opacities or" exact="focal" post="unilateral/bilateral consolidation. Chest radiography or CT abnormal rate was"/>
  <result pre="CT abnormal rate was &amp;gt;94% Unilateral/bilateral patchy densities or infiltrates," exact="bilateral" post="hilar infiltration, segmented/lobar opacities, ground-glass opacities and possible small"/>
  <result pre="bilateral hilar infiltration, segmented/lobar opacities, ground-glass opacities and possible small" exact="pleural" post="effusions.Â Chest radiography or CT abnormal rate was between"/>
  <result pre="also increased IL-1Î², IL-6, IL-12, IFN-Î³, IP10Â and MCP-1 increased" exact="Increased" post="concentrations of proinflammatory cytokines (IFN-Î³, TNF-Î±, IL-15Â and IL-17)"/>
  <result pre="[6,50] Treatment medicine Corticosteroids, remdesivir, combination of lopinavir and ritonavir," exact="type I" post="interferon and so on Lopinavir and ritonavir, corticosteroids, IFN-Î±,"/>
  <result pre="GMCSF: Granulocyte/monocyte colony stimulating factor;Â ICU: Intensive care unit;Â IFN-Î±:" exact="Type 1" post="interferon; IFN-Î²: Interferon beta;Â IFN-Î³: Interferon gama; IL-1Î²: Interleukin"/>
  <result pre="15;Â IL-17: Interleukin 17;Â IVIG: Intravenous immunoglobulin;Â MERS-CoV: Middle East" exact="respiratory" post="syndrome coronavirus;Â TNF-Î±: tumor necrosis factor-alpha; VEGF: Vascularendothelial growth"/>
  <result pre="IL-17: Interleukin 17;Â IVIG: Intravenous immunoglobulin;Â MERS-CoV: Middle East respiratory" exact="syndrome" post="coronavirus;Â TNF-Î±: tumor necrosis factor-alpha; VEGF: Vascularendothelial growth factor;Â"/>
  <result pre="IVIG: Intravenous immunoglobulin;Â MERS-CoV: Middle East respiratory syndrome coronavirus;Â TNF-Î±:" exact="tumor" post="necrosis factor-alpha; VEGF: Vascularendothelial growth factor;Â SARS-CoV-2: Severe acute"/>
  <result pre="coronavirus;Â TNF-Î±: tumor necrosis factor-alpha; VEGF: Vascularendothelial growth factor;Â SARS-CoV-2:" exact="Severe" post="acute respiratory syndrome coronavirus 2. The virus can be"/>
  <result pre="TNF-Î±: tumor necrosis factor-alpha; VEGF: Vascularendothelial growth factor;Â SARS-CoV-2: Severe" exact="acute" post="respiratory syndrome coronavirus 2. The virus can be transmitted"/>
  <result pre="tumor necrosis factor-alpha; VEGF: Vascularendothelial growth factor;Â SARS-CoV-2: Severe acute" exact="respiratory" post="syndrome coronavirus 2. The virus can be transmitted not"/>
  <result pre="necrosis factor-alpha; VEGF: Vascularendothelial growth factor;Â SARS-CoV-2: Severe acute respiratory" exact="syndrome" post="coronavirus 2. The virus can be transmitted not only"/>
  <result pre="A Lancet report demonstrated that the virus could have recently" exact="acquired" post="the ability to transmit between humans [6]. A report"/>
  <result pre="family settings [23]. SARS-CoV-2 can spread via direct contact and" exact="respiratory" post="droplets. Respiratory particles are spread while breathing, speaking, coughing"/>
  <result pre="[23]. SARS-CoV-2 can spread via direct contact and respiratory droplets." exact="Respiratory" post="particles are spread while breathing, speaking, coughing or sneezing"/>
  <result pre="Journal of Medicine [25]. Aerosolized virus may be generated by" exact="respiratory" post="and surgical procedures. The study showed that the half-life"/>
  <result pre="the virus on plastic, stainless steel, copper and cardboard remained" exact="stable" post="for 4â€&quot;72Â h [25]. These results indicate that aerosol"/>
  <result pre="results ranged from 1 to 12Â days [27]. In addition," exact="viral" post="nucleic acid in 64.29% patients remained positive in the"/>
  <result pre="rate within Wuhan of 1.94Â days (95% CI: 1.25â€&quot;6.71), an" exact="infectious" post="period of 1.61Â days (95% CI: 0.35â€&quot;3.23) and an"/>
  <result pre="transmission rate than that of SARS-CoV and MERS-CoV. Variation in" exact="viral" post="transmissibility should be considered, and estimates of the reproduction"/>
  <result pre="organization and the encoded proteins of SARS-CoV-2, SARS-CoV and MERS-CoV." exact="Structural" post="proteins included spikeÂ (S), envelope (E), membrane (M) and"/>
  <result pre="(FigureÂ 1A) [36]. The S protein mediates entrance into human" exact="respiratory" post="epithelial cells by interacting with the cell-surface receptor angiotensin-converting"/>
  <result pre="1A) [36]. The S protein mediates entrance into human respiratory" exact="epithelial" post="cells by interacting with the cell-surface receptor angiotensin-converting enzyme"/>
  <result pre="the virus. Clinical characteristics of patients infected with SARS-CoV-2 SARS-CoV-2" exact="infection" post="has caused clusters of severe respiratory illness similar to"/>
  <result pre="infected with SARS-CoV-2 SARS-CoV-2 infection has caused clusters of severe" exact="respiratory" post="illness similar to that of SARS-CoV. The virus causes"/>
  <result pre="virus causes symptoms such as fever, cough, shortness of breath," exact="leukopenia" post="and pneumonia in both lungs [6]. The symptoms are"/>
  <result pre="symptoms such as fever, cough, shortness of breath, leukopenia and" exact="pneumonia" post="in both lungs [6]. The symptoms are observed approximately"/>
  <result pre="The symptoms are observed approximately 5.2Â days after the SARS-CoV-2" exact="infection" post="[5]. In a study published in The Lancet, 41"/>
  <result pre="of 41 patients who were identified as positive for SARS-CoV-2" exact="infection" post="presented with pneumonia and abnormal chest computed tomography (CT)"/>
  <result pre="who were identified as positive for SARS-CoV-2 infection presented with" exact="pneumonia" post="and abnormal chest computed tomography (CT) [6]. COVID-19 symptoms"/>
  <result pre="as positive for SARS-CoV-2 infection presented with pneumonia and abnormal" exact="chest" post="computed tomography (CT) [6]. COVID-19 symptoms included fever (98%),"/>
  <result pre="such as sputum production (28%), headache (8%), hemoptysis (5%) and" exact="diarrhea" post="(3%), were also observed [6]. Another clinical study containing"/>
  <result pre="(TableÂ 1Â &amp;amp;Â FigureÂ 2) [5]. Common complications included shock," exact="acute" post="respiratory distress syndrome, acute renal injury, acute liver failure,"/>
  <result pre="1Â &amp;amp;Â FigureÂ 2) [5]. Common complications included shock, acute" exact="respiratory" post="distress syndrome, acute renal injury, acute liver failure, arrhythmia,"/>
  <result pre="2) [5]. Common complications included shock, acute respiratory distress syndrome," exact="acute" post="renal injury, acute liver failure, arrhythmia, RNAaemia and acute"/>
  <result pre="complications included shock, acute respiratory distress syndrome, acute renal injury," exact="acute" post="liver failure, arrhythmia, RNAaemia and acute cardiac injury [45]."/>
  <result pre="included shock, acute respiratory distress syndrome, acute renal injury, acute" exact="liver failure," post="arrhythmia, RNAaemia and acute cardiac injury [45]. In addition,"/>
  <result pre="syndrome, acute renal injury, acute liver failure, arrhythmia, RNAaemia and" exact="acute" post="cardiac injury [45]. In addition, it is now understood"/>
  <result pre="Most patients had haemoptysis dyspnea, fever, headache, fatigue, sputum production," exact="pneumonia" post="and ground-glass opacities. However, only a low percentage of"/>
  <result pre="a low percentage of patients developed intestinal symptoms such as" exact="diarrhea" post="and vomiting. Leucopenia, lymphopenia, pro-inflammation cytokines increasing, acute respiratory"/>
  <result pre="such as diarrhea and vomiting. Leucopenia, lymphopenia, pro-inflammation cytokines increasing," exact="acute" post="respiratory distress syndrome and acute organs damages (such as"/>
  <result pre="as diarrhea and vomiting. Leucopenia, lymphopenia, pro-inflammation cytokines increasing, acute" exact="respiratory" post="distress syndrome and acute organs damages (such as cardiac,"/>
  <result pre="and vomiting. Leucopenia, lymphopenia, pro-inflammation cytokines increasing, acute respiratory distress" exact="syndrome" post="and acute organs damages (such as cardiac, liver or"/>
  <result pre="Leucopenia, lymphopenia, pro-inflammation cytokines increasing, acute respiratory distress syndrome and" exact="acute" post="organs damages (such as cardiac, liver or kidney) were"/>
  <result pre="care unit patients. One study showed that during the early" exact="infection" post="period, most patients had normal white blood cell counts;"/>
  <result pre="normal white blood cell counts; however, 56.8% of patients had" exact="leukopenia" post="in cases of serious infection [46]. Patients with dyspnea"/>
  <result pre="however, 56.8% of patients had leukopenia in cases of serious" exact="infection" post="[46]. Patients with dyspnea were more frequently admitted to"/>
  <result pre="frequently admitted to the intensive care unit (ICU) [46]. Most" exact="chest" post="computed tomography (CT) showed bilateral patchy shadows or ground-glass"/>
  <result pre="care unit (ICU) [46]. Most chest computed tomography (CT) showed" exact="bilateral" post="patchy shadows or ground-glass opacity (GGO) in the lungs"/>
  <result pre="[5,6]. In another study, 86% of patients showed GGO by" exact="chest" post="CT, and 29% of patients had consolidation [47]. Following"/>
  <result pre="reticular or interlobular septal thickening [48]. However, no direct cavitation," exact="pleural" post="effusion, lymphadenopathy or nodules were observed in the lungs"/>
  <result pre="of the large amounts of cytokines produced during SARS-CoV infection," exact="infection" post="with SARS-CoV-2 similarly induces the production of proinflammatory cytokines"/>
  <result pre="as, interleukin 1 beta (IL-1Î²), interferon gamma (IFN-Î³), IP10Â and" exact="monocyte" post="chemoattractant protein 1 (MCP). Moreover, the levels of granulocyte"/>
  <result pre="of granulocyte colony stimulating factor (GCSF), IP10, MCP1, MIP1Î±Â and" exact="tumor" post="necrosis factor- alphaÂ (TNF-Î±) were found to be higher"/>
  <result pre="cytokines (e.g.,interleukin 4Â [IL-4]Â and interleukin 10 [IL-10]Â by T-helper" exact="type 2" post="[Th2] cells was also increased during SARS-CoV-2 infection [6])"/>
  <result pre="T-helper type 2 [Th2] cells was also increased during SARS-CoV-2" exact="infection" post="[6]) (TableÂ 1). The mortality rate of SARS-CoV-2-infected patients"/>
  <result pre="[11]. The currently estimated mortality rate of SARS-CoV-2 is therefore" exact="lower" post="than that of SARS-CoV and MERS-CoV [51,52] (TableÂ 1)."/>
  <result pre="In summary, SARS-CoV-2 spreads more rapidly but has a relatively" exact="lower" post="fatality rate as compared with two other related coronaviruses."/>
  <result pre="related coronaviruses. Diagnostic laboratory testing Hematology testing The number of" exact="total" post="leukocytes, lymphocytes and monocytes has been detected from hospitalized"/>
  <result pre="hospitalized patients with COVID-19 [53]. Approximately 25% of cases formed" exact="leucopenia" post="[6]. Moreover, lymphopenia was observed in 63â€&quot;70.3% of patients"/>
  <result pre="COVID-19 [53]. Approximately 25% of cases formed leucopenia [6]. Moreover," exact="lymphopenia" post="was observed in 63â€&quot;70.3% of patients [5,6]. CD4+ or"/>
  <result pre="patients [5,6]. CD4+ or CD8+ T-cell numbers decreased as the" exact="disease" post="severity increased [6,54]. Patients with severe cases had more"/>
  <result pre="acid testing Virus from throat swabs, blood, urine, stool or" exact="respiratory" post="tracts have been assessed by fluorescent reverse transcription-polymerase chain"/>
  <result pre="limit of detection (LOD) of RdRp/Hel and N gene was" exact="lower" post="than that of S gene and RdRp-P2 [18]. Chan"/>
  <result pre="rate and improve the laboratory diagnosis of COVID-19 [18]. SARS-CoV-2" exact="viral" post="load is detectable from throat- and lung-derived samples; however,"/>
  <result pre="yet yielded virus [56]. Patients with COVID-19 produced the highest" exact="viral" post="load near symptom presentation, which may be the reason"/>
  <result pre="spread of the virus [57]. An observational cohort showed that" exact="viral" post="load in saliva was highest following symptom onset in"/>
  <result pre="first week, then gradually declined with time [56]. Endotracheal aspirate" exact="viral" post="load was available from day 8 after symptom onset"/>
  <result pre="be detected for 20Â days or longer in that study." exact="Viral" post="load in respiratory tract specimens was about sixfold higher"/>
  <result pre="20Â days or longer in that study. Viral load in" exact="respiratory" post="tract specimens was about sixfold higher than that in"/>
  <result pre="than that of younger patients. Studies showed that higher initial" exact="viral" post="load was related to the severity of COVID-19 symptoms"/>
  <result pre="should be combined with CT scans and nucleic acid testing." exact="Viral" post="genome sequencing Bronchoalveolar lavage fluid or throat swabs from"/>
  <result pre="fluid or throat swabs from patients have been sequenced, and" exact="viral" post="genomes were searched via BLAST with the SARS-CoV-2 sequence"/>
  <result pre="important for patients who present late with a very low" exact="viral" post="load, below the detection limit of RT-PCR assays [59]."/>
  <result pre="serological testing may be used to confirm current or previous" exact="infection" post="with SARS-CoV-2. Animal models for COVID-19 An ideal animal"/>
  <result pre="ideal animal model for COVID-19 would reflect the clinical signs," exact="viral" post="replication and pathology displayed in humans. Non-human primate models"/>
  <result pre="pathology displayed in humans. Non-human primate models (rhesus, cynomolgus macaques," exact="African" post="green monkeys, common marmoset, squirrel monkeys and mustached tamarins)"/>
  <result pre="mustached tamarins) have all been evaluated as models of SARS-CoV" exact="infection" post="[62]. All non-human primates had pneumonia, cough and respiratory"/>
  <result pre="SARS-CoV infection [62]. All non-human primates had pneumonia, cough and" exact="respiratory" post="distress after virus infection [15]. Mice (BALB/c, C57BL6 and"/>
  <result pre="All non-human primates had pneumonia, cough and respiratory distress after" exact="virus infection" post="[15]. Mice (BALB/c, C57BL6 and 129S strains) supported SARS-CoV"/>
  <result pre="non-human primates had pneumonia, cough and respiratory distress after virus" exact="infection" post="[15]. Mice (BALB/c, C57BL6 and 129S strains) supported SARS-CoV"/>
  <result pre="to study immuno-prophylaxis and drug research as they harbored high" exact="viral" post="titers and pulmonary histopathology upon virus infection [63]. Ferrets"/>
  <result pre="and drug research as they harbored high viral titers and" exact="pulmonary" post="histopathology upon virus infection [63]. Ferrets are another appropriate"/>
  <result pre="as they harbored high viral titers and pulmonary histopathology upon" exact="virus infection" post="[63]. Ferrets are another appropriate animal model to study"/>
  <result pre="they harbored high viral titers and pulmonary histopathology upon virus" exact="infection" post="[63]. Ferrets are another appropriate animal model to study"/>
  <result pre="[63]. Ferrets are another appropriate animal model to study this" exact="respiratory" post="virus because the clinical symptoms, viral titers and histologic"/>
  <result pre="model to study this respiratory virus because the clinical symptoms," exact="viral" post="titers and histologic changes were similar to those of"/>
  <result pre="and histologic changes were similar to those of patients with" exact="virus infection" post="[63]. ACE2, the receptor of SARS-CoV, was also identified"/>
  <result pre="histologic changes were similar to those of patients with virus" exact="infection" post="[63]. ACE2, the receptor of SARS-CoV, was also identified"/>
  <result pre="reported in Science shows that SARS-CoV-2 can replicate in the" exact="upper" post="respiratory tract of ferrets, indicating that ferrets represent an"/>
  <result pre="in Science shows that SARS-CoV-2 can replicate in the upper" exact="respiratory" post="tract of ferrets, indicating that ferrets represent an ideal"/>
  <result pre="COVID-19 [64]. In addition, the domestic cat has shown multifocal" exact="pulmonary" post="consolidation with infection of SARS-CoV, and SARS-CoV-2 can replicate"/>
  <result pre="addition, the domestic cat has shown multifocal pulmonary consolidation with" exact="infection" post="of SARS-CoV, and SARS-CoV-2 can replicate efficiently in cats"/>
  <result pre="aureus and is combined with nemonoxacin in cases of severe" exact="infection" post="[65]. A combination of lopinavir and ritonavir has been"/>
  <result pre="has demonstrated effective pan-CoV therapy. The first case of SARS-CoV-2" exact="infection" post="in the USA was successfully treated with RDA. Moreover,"/>
  <result pre="Favipiravir is a nucleoside analog that can lead to lethal" exact="viral" post="mutagenesis, chain termination or the inhibition of nucleotide biosynthesis"/>
  <result pre="(ARB) was licensed for the treatment of influenza and other" exact="respiratory" post="viral infections in Russia and China [72,73]. Blaising and"/>
  <result pre="was licensed for the treatment of influenza and other respiratory" exact="viral" post="infections in Russia and China [72,73]. Blaising and coauthors"/>
  <result pre="licensed for the treatment of influenza and other respiratory viral" exact="infections" post="in Russia and China [72,73]. Blaising and coauthors consider"/>
  <result pre="have been commonly used in patients with SARS-CoV or MERS-CoV" exact="infection" post="[74,75]. Glucocorticoids prolonged the survival time of SARS cases"/>
  <result pre="decrease with corticosteroid treatment in patients infected with SARS-CoV-2, and" exact="viral" post="clearance was not delayed [6,74]. Therefore, it is still"/>
  <result pre="still controversial whether corticosteroids should be used to treat SARS-CoV-2" exact="infections" post="[69]. Chloroquine/hydroxychloroquine was used as an antimalarial, broad spectrum"/>
  <result pre="broad spectrum antiviral drug, and has been broadly used in" exact="autoimmune diseases" post="including lupus and rheumatoid arthritisÂ [76]. A recent study"/>
  <result pre="drug, and has been broadly used in autoimmune diseases including" exact="lupus" post="and rheumatoid arthritisÂ [76]. A recent study indicates that"/>
  <result pre="medical advisory. Chloroquine has been highly effective in reducing SARS-CoV-2" exact="viral" post="replication by increasing endosomal pH and interfering with the"/>
  <result pre="inhibits IL-6 signaling and is used as a treatment in" exact="rheumatoid arthritis" post="[79]. IL-6 is one of the most important cytokines"/>
  <result pre="IL-6 signaling and is used as a treatment in rheumatoid" exact="arthritis" post="[79]. IL-6 is one of the most important cytokines"/>
  <result pre="in the latest version of the Diagnosis and Treatment of" exact="pneumonia" post="induced by COVID-19 [81]. In addition, human seroalbumin and"/>
  <result pre="seroalbumin and Î³-immunoglobulin were given to some patients with severe" exact="infections" post="[82]. In conclusion, there are specific vaccines or antiviral"/>
  <result pre="further study. ConclusionÂ &amp;amp; prospects COVID-19 is a serious human" exact="infectious disease" post="of global concern. As of 7Â April 2020, SARS-CoV-2"/>
  <result pre="study. ConclusionÂ &amp;amp; prospects COVID-19 is a serious human infectious" exact="disease" post="of global concern. As of 7Â April 2020, SARS-CoV-2"/>
  <result pre="concern. As of 7Â April 2020, SARS-CoV-2 has infected a" exact="total" post="of 134,784 patients globally at least (FigureÂ 3D &amp;amp;"/>
  <result pre="Although the overall mortality rate of SARS-CoV-2 appears to be" exact="lower" post="than that of SARS-CoV and MERS-CoV (TableÂ 1), the"/>
  <result pre="Moreover, the fatality rate of elderly patients with reduced immunity" exact="or chronic" post="diseases is as high as 15% [6]. In addition,"/>
  <result pre="the fatality rate of elderly patients with reduced immunity or" exact="chronic" post="diseases is as high as 15% [6]. In addition,"/>
  <result pre="laboratory-confirmed cases, cured cases and death cases of 2019 coronavirus" exact="disease" post="(COVID-19). Distribution of laboratory-confirmed cases, cured cases and death"/>
  <result pre="laboratory-confirmed cases, cured cases and death cases of 2019 coronavirus" exact="disease" post="(COVID-19 (A, B &amp;amp;Â C) in China by province/region"/>
  <result pre="laboratory-confirmed cases, cured cases and death cases of 2019 coronavirus" exact="disease" post="(COVID-19) globally by country as of 7 April 2020."/>
  <result pre="medical staff from other areas were deployed to help prevent" exact="infections" post="in Wuhan [84]. The WHO and various governments advised"/>
  <result pre="social distance, wear masks, wash their hands frequently, and practice" exact="respiratory" post="hygiene. As ofÂ 7Â April 2020, the number of"/>
  <result pre="isolated any suspected cases as rapidly as possible to contain" exact="infection" post="and prevent local outbreaks. The ability to rapidly test"/>
  <result pre="ability to rapidly test patients suspected of having a SARS-CoV-2" exact="infection" post="is the cornerstone of case isolation. The experience gained"/>
  <result pre="last 20Â years could also help in dealing with SARS-CoV-2" exact="infections" post="throughout the world. Future perspective To date, no SARS-CoV-2-specific"/>
  <result pre="vaccines have been described for COVID-19. Therefore, a safe and" exact="stable" post="vaccine for COVID-19 is urgently needed, and it is"/>
  <result pre="for COVID-19 also will be widely developed. Meanwhile, the origin," exact="intermediate" post="host, structure and pathogenesis of SARS-CoV-2 will be the"/>
  <result pre="advance to prevent epidemics in the world. Executive summary Coronavirus" exact="disease" post="2019 (COVID-19) was first reported in China and currently"/>
  <result pre="in China and currently poses a serious challenge worldwide. The" exact="pneumonia" post="was caused by a novel coronavirus named SARS-CoV-2. More"/>
  <result pre="previous coronavirus outbreaks, COVID-19 has been reported to have a" exact="lower" post="mortality rate and more rapid transmissibility and caused severe"/>
  <result pre="lower mortality rate and more rapid transmissibility and caused severe" exact="acute" post="respiratory syndrome similarly to SARS. The main symptoms are"/>
  <result pre="mortality rate and more rapid transmissibility and caused severe acute" exact="respiratory" post="syndrome similarly to SARS. The main symptoms are fever,"/>
  <result pre="rate and more rapid transmissibility and caused severe acute respiratory" exact="syndrome" post="similarly to SARS. The main symptoms are fever, cough,"/>
  <result pre="SARS. The main symptoms are fever, cough, shortness of breath," exact="leukopenia" post="and pneumonia. Diagnostic laboratory testing of COVID-19 includes hematology"/>
  <result pre="laboratory testing of COVID-19 includes hematology testing, nucleic acid testing," exact="viral" post="genome sequencing and serology testing. To date, no specific"/>
  <result pre="infection. Traditional Chinese medicines are also used for therapy during" exact="infection" post="with SARS-CoV-2. This review is presented in the hope"/>
  <result pre="PanCLessons learned from the 2019-nCoV epidemic on prevention of future" exact="infectious diseases." post="Microbes Infect.22(2), 86â€&quot;91 (2020).32088333 4.HanQ , LinQ , JinS"/>
  <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China. JAMA (2020) (Epub ahead of print)."/>
  <result pre=", ChenDClinical and epidemiological features of 36 children with coronavirus" exact="disease" post="2019 (COVID-19) in Zhejiang, China: an observational cohort study."/>
  <result pre="area or both exposures. Symptoms are similar to that of" exact="adult" post="patients. 8.GralinskiLE , MenacheryVDReturn of the coronavirus: 2019-nCoV. Viruses12(2),"/>
  <result pre="(2015).26206723 10.ReinaJ , Lopez-CausapeC , Rojo-MolineroE , RubioRClinico-epidemiological characteristics of" exact="acute" post="respiratory infections caused by coronavirus OC43, NL63 and 229E."/>
  <result pre="10.ReinaJ , Lopez-CausapeC , Rojo-MolineroE , RubioRClinico-epidemiological characteristics of acute" exact="respiratory" post="infections caused by coronavirus OC43, NL63 and 229E. Rev."/>
  <result pre=", Lopez-CausapeC , Rojo-MolineroE , RubioRClinico-epidemiological characteristics of acute respiratory" exact="infections" post="caused by coronavirus OC43, NL63 and 229E. Rev. Clin."/>
  <result pre="247â€&quot;258 (2015). 16.JiangS , DuL , ShiZAn emerging coronavirus causing" exact="pneumonia" post="outbreak in Wuhan, China: calling for developing therapeutic and"/>
  <result pre="vitro and did not cross-react with other human-pathogenic coronaviruses and" exact="respiratory" post="pathogens. The positive rate of RdRp/Hel assay is higher"/>
  <result pre="Cell181(2), 281â€&quot;292; e286 (2020).32155444 20.ZhouP , YangXL , WangXGet al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="(Epub ahead of print). 23.ChanJF , YuanS , KokKHet al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="print). 23.ChanJF , YuanS , KokKHet al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="SARS-CoV-2 is plausible, as the virus can remain viable and" exact="infectious" post="in aerosols for hours and on surfaces for up"/>
  <result pre="26.LiJY , YouZ , WangQet al.The epidemic of 2019-novel-coronavirus (2019-nCoV)" exact="pneumonia" post="and insights for emerging infectious diseases in the future."/>
  <result pre="al.The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging" exact="infectious diseases" post="in the future. Microbes Infect.22(2), 80â€&quot;85 (2020).32087334 27.XiaoF ,"/>
  <result pre=", ZhengX , LiuY , LiX , ShanHEvidence for gastrointestinal" exact="infection" post="of SARS-CoV-2. Gastroenterology158(6), 1831â€&quot;1833 (2020).32142773 28.ChenY , ChenL ,"/>
  <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting Wuhan. Emerg. Microbes Infect.9(1), 221â€&quot;236 (2020).31987001 39.WuA"/>
  <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting Wuhan. Emerg. Microbes Infect.9(1), 221â€&quot;236 (2020).31987001 39.WuA"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet395(10223), 507â€&quot;513 (2020).32007143"/>
  <result pre="LinM , WeiLet al.Epidemiologic and clinical characteristics of novel coronavirus" exact="infections" post="involving 13 patients outside Wuhan, China. JAMA (2020) (Epub"/>
  <result pre="coronavirus (2019-nCoV). Radiology295(1), 202â€&quot;207 (2020). 32017661 â€¢ Shows the characteristic" exact="chest" post="CT imaging features of COVID-19 patients. Out of 21"/>
  <result pre="patients, 71% had involvement of more than two lobes at" exact="chest" post="CT, 57% had ground-glass opacities, 33% had opacities with"/>
  <result pre="33% had opacities with a rounded morphology, 33% had a" exact="peripheral" post="distribution of disease, 29% had consolidation with ground-glass opacities"/>
  <result pre="210â€&quot;217 (2020).32027573 49.KanneJPChest CT Findings in 2019 novel coronavirus (2019-nCoV)" exact="infections" post="from Wuhan, China: key points for the radiologist. Radiology295(1),"/>
  <result pre="(2013).23831143 53.LaiCC , ShihTP , KoWC , TangHJ , HsuehPRSevere" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
  <result pre="53.LaiCC , ShihTP , KoWC , TangHJ , HsuehPRSevere acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the"/>
  <result pre=", ShihTP , KoWC , TangHJ , HsuehPRSevere acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
  <result pre=", WangTet al.Diagnosis, treatment, and prevention of 2019 novel coronavirus" exact="infection" post="in children: experts' consensus statement. World J. Pediatr. (2020)"/>
  <result pre="of print). 57.ToKK , TsangOT , LeungWSet al.Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
  <result pre=", TsangOT , LeungWSet al.Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
  <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis.20(5),"/>
  <result pre="al.Diagnostic value and dynamic variance of serum antibody in coronavirus" exact="disease" post="2019. Int. J. Infect. Dis.94, 49â€&quot;52 (2020).32251798 62.GongSR ,"/>
  <result pre="WangW , ChenXTherapeutic and triage strategies for 2019 novel coronavirus" exact="disease" post="in fever clinics. Lancet Resp. Med.8(3), e11â€&quot;e12 (2020). 66.MomattinH"/>
  <result pre="of therapeutic agents for the treatment of the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV). Travel Med. Infect. Dis.30, 9â€&quot;18 (2019).31252170"/>
  <result pre="therapeutic agents for the treatment of the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV). Travel Med. Infect. Dis.30, 9â€&quot;18 (2019).31252170 67.StockmanLJ"/>
  <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
  <result pre="69â€&quot;71 (2020).31996494 71.BleibtreuA , JaureguiberryS , HouhouNet al.Clinical management of" exact="respiratory" post="syndrome in patients hospitalized for suspected Middle East respiratory"/>
  <result pre="(2020).31996494 71.BleibtreuA , JaureguiberryS , HouhouNet al.Clinical management of respiratory" exact="syndrome" post="in patients hospitalized for suspected Middle East respiratory syndrome"/>
  <result pre="of respiratory syndrome in patients hospitalized for suspected Middle East" exact="respiratory" post="syndrome coronavirus infection in the Paris area from 2013"/>
  <result pre="respiratory syndrome in patients hospitalized for suspected Middle East respiratory" exact="syndrome" post="coronavirus infection in the Paris area from 2013 to"/>
  <result pre="in patients hospitalized for suspected Middle East respiratory syndrome coronavirus" exact="infection" post="in the Paris area from 2013 to 2016. BMC"/>
  <result pre=", LiuYY , WeiFet al.Antiviral activity of arbidol hydrochloride against" exact="herpes" post="simplex virus I in vitro and in vivo. Int."/>
  <result pre="treatment for 2019-nCoV lung injury. Lancet395(10223), 473â€&quot;475 (2020).32043983 75.PanesarNSWhat caused" exact="lymphopenia" post="in SARS and how reliable is the lymphokine status"/>
  <result pre="105923 (2020).32070753 78.YuanJ , ZouR , ZengLet al.The correlation between" exact="viral" post="clearance and biochemical outcomes of 94 COVID-19 infected discharged"/>
  <result pre=", WuZ , LiJW , ZhaoH , WangGQThe cytokine release" exact="syndrome" post="(CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist"/>
  <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version). Military Med. Res.7(1), 4 (2020). 83.ZhangY ,"/>
  <result pre="e99â€&quot;e101 (2020).32087216 84.JinH , LiuJ , CuiM , LuLNovel coronavirus" exact="pneumonia" post="emergency in Zhuhai: impact and challenges. J. Hosp. Infect.104(4),"/>
  <result pre="BertineM , BertinC , Houhou-FidouhN , VisseauxBFocus on Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV). Med. Mal. Infect.50(3), 243â€&quot;251 (2020).31727466"/>
  <result pre=", BertinC , Houhou-FidouhN , VisseauxBFocus on Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV). Med. Mal. Infect.50(3), 243â€&quot;251 (2020).31727466"/>
 </snippets>
</snippetsTree>
